Literature DB >> 19945613

Epidermolysis bullosa simplex.

Eli Sprecher1.   

Abstract

The prevalence of epidermolysis bullosa simplex (EBS) is estimated to be approximately 6 to 30 per 1 million live births. The disease is usually caused by missense mutations in KRT5 and KRT14, encoding keratins mostly expressed in the epidermal basal layer. Major advances in understanding of the molecular basis of EBS and other keratin disorders have led to the development of DNA-based prenatal testing.

Entities:  

Mesh:

Year:  2010        PMID: 19945613     DOI: 10.1016/j.det.2009.10.003

Source DB:  PubMed          Journal:  Dermatol Clin        ISSN: 0733-8635            Impact factor:   3.478


  8 in total

Review 1.  Epidermolysis bullosa and the partnership with autoimmunity: what should we assimilate?

Authors:  Susanna Esposito; Sophie Guez; Francesca Manzoni; Annalisa Bosco; Donato Rigante
Journal:  Immunol Res       Date:  2015-02       Impact factor: 2.829

Review 2.  Squamous Cell Carcinoma in Patients with Inherited Epidermolysis Bullosa: Review of Current Literature.

Authors:  Domenico Bonamonte; Angela Filoni; Aurora De Marco; Lucia Lospalluti; Eleonora Nacchiero; Valentina Ronghi; Anna Colagrande; Giuseppe Giudice; Gerardo Cazzato
Journal:  Cells       Date:  2022-04-17       Impact factor: 7.666

3.  The use of cultured allogenic keratinocyte grafting in a patient with epidermolysis bullosa simplex.

Authors:  Kee Cheol Shin; Bo Young Park; Han Koo Kim; Woo Seob Kim; Tae Hui Bae
Journal:  Ann Dermatol       Date:  2011-12-27       Impact factor: 1.444

4.  Treatment of symptomatic epidermolysis bullosa simplex with botulinum toxin in a pediatric patient.

Authors:  Heather M Holahan; Ronda S Farah; Nkanyezi N Ferguson; Amy S Paller; Allison A Legler
Journal:  JAAD Case Rep       Date:  2016-07-14

Review 5.  Keratins as an Inflammation Trigger Point in Epidermolysis Bullosa Simplex.

Authors:  Nadezhda A Evtushenko; Arkadii K Beilin; Anastasiya V Kosykh; Ekaterina A Vorotelyak; Nadya G Gurskaya
Journal:  Int J Mol Sci       Date:  2021-11-18       Impact factor: 5.923

6.  Inherited epidermolysis bullosa: clinical and therapeutic aspects.

Authors:  Vanessa Lys Simas Yamakawa Boeira; Erica Sales Souza; Bruno de Oliveira Rocha; Pedro Dantas Oliveira; Maria de Fátima Santos Paim de Oliveira; Vitória Regina Pedreira de Almeida Rêgo; Ivonise Follador
Journal:  An Bras Dermatol       Date:  2013 Mar-Apr       Impact factor: 1.896

Review 7.  Genetic burden linked to founder effects in Saguenay-Lac-Saint-Jean illustrates the importance of genetic screening test availability.

Authors:  Mbarka Bchetnia; Luigi Bouchard; Jean Mathieu; Philippe M Campeau; Charles Morin; Diane Brisson; Anne-Marie Laberge; Hélène Vézina; Daniel Gaudet; Catherine Laprise
Journal:  J Med Genet       Date:  2021-04-28       Impact factor: 6.318

Review 8.  Immunological mechanisms underlying progression of chronic wounds in recessive dystrophic epidermolysis bullosa.

Authors:  Leonie Huitema; Taylor Phillips; Vitali Alexeev; Olga Igoucheva
Journal:  Exp Dermatol       Date:  2021-06-27       Impact factor: 4.511

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.